- Primary and all major secondary efficacy endpoints were highly statistically significant
- Rilonacept treatment resulted in a 96% reduction in risk of recurrent pericarditis events (primary efficacy endpoint: Hazard Ratio = 0.04, p
Kiniksa Announces Positive Data from Phase 3 Trial of Rilonacept in Recurrent Pericarditis (RHAPSODY)
Kiniksa Pharmaceuticals International, plc on 6ix
In the deck
Story so far
- Kiniksa Provides Timing of Second Half 2020 Clinical Data Readouts
- Kiniksa Announces 28-Day Clinical Outcomes Data from Mavrilimumab Treatment Protocol in Severe COVID-19 Pneumonia and Active U.S. IND for Phase 2/3 Clinical Trial
- Kiniksa Reports Data for Mavrilimumab in COVID-19 Pneumonia and Hyperinflammation and for Vixarelimab in Diseases Characterized by Chronic Pruritus
Earlier from Kiniksa Pharmaceuticals International
- Kiniksa Announces Lancet Rheumatology Publication of Clinical Outcomes with Mavrilimumab in COVID-19
- Kiniksa Provides Timing of Second Half 2020 Clinical Data Readouts
- Kiniksa Announces 28-Day Clinical Outcomes Data from Mavrilimumab Treatment Protocol in Severe COVID-19 Pneumonia and Active U.S. IND for Phase 2/3 Clinical Trial
- Kiniksa Pharmaceuticals to Present at 41st Annual Goldman Sachs Global Healthcare Conference
- Kiniksa Announces Upcoming Presentation on Mavrilimumab in COVID-19 Pneumonia and Hyperinflammation at the European E-Congress of Rheumatology 2020
Later from Kiniksa Pharmaceuticals International
- Kiniksa Announces U.S. Orphan Drug Designation for Rilonacept for the Treatment of Pericarditis
- Kiniksa Pharmaceuticals, Ltd. Announces Proposed Public Offering
- Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Upsized Public Offering
- Kiniksa Reports Second Quarter 2020 Financial Results and Highlights Recent Pipeline and Corporate Activity
- Kiniksa Pharmaceuticals to Present at the 2020 Wedbush PacGrow Healthcare Conference
Follow Kiniksa Pharmaceuticals International into a list and get an email when it puts out news.
Follow Kiniksa Pharmaceuticals International